HPV vaccination after lesion treatment is likely cost-effective

October 11, 2017

(HealthDay)—For HIV-infected men who have sex with men (MSM), adjuvant quadrivalent human papillomavirus vaccination (qHPV) after treatment of high-grade squamous intraepithelial lesions (HSIL) is likely to be cost-effective, according to a study published online Sept. 12 in Vaccine.

Ashish A. Deshmukh, Ph.D., M.P.H., from the University of Florida, Gainesville, and colleagues developed a Markov (state-transition) cohort model to assess the cost-effectiveness of post-HSIL HPV vaccination of HIV-infected MSM (aged 27 and older).

Using the willingness-to-pay threshold of $100,000 per quality-adjusted life-year, the researchers found that treatment plus vaccination was the most cost-effective HSIL management strategy, with an incremental cost-effectiveness ratio of $71,937 per quality-adjusted life-year. The population-level expected value of perfect information for conducting future clinical research evaluating HSIL management approaches was $12 million. The expected value of partial perfect information associated with adjuvant qHPV vaccination efficacy, estimated in terms of hazards of decreasing HSIL recurrence, was $0, suggesting that additional data from a future study evaluating efficacy of adjuvant qHPV vaccination would not change the conclusion that treatment plus vaccination was cost-effective.

"Use of adjuvant qHPV vaccination could be considered as a potential strategy to reduce rising anal cancer burden among these high-risk individuals," conclude the authors.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Explore further: How the anal cancer epidemic in gay and bi HIV-positive men can be prevented

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

How the anal cancer epidemic in gay and bi HIV-positive men can be prevented

September 27, 2017
Almost 620,000 gay and bisexual men in the United States were living with HIV in 2014, and 100,000 of these men were not even aware of their infection. These men are 100 times more likely to have anal cancer than HIV-negative ...

Study outlines recommendations for precancerous treatment of anal lesions

September 27, 2017
Currently, no guidelines exist for screening and treatment of precancerous anal lesions or for anal cancer screening because enough is not known about the effectiveness of treating lesions detected through screening. A new ...

HPV vaccination not associated with increased risk of multiple sclerosis, study shows

January 6, 2015
Although some reports have suggested a link between human papillomavirus (HPV) vaccination and development of multiple sclerosis or other demyelinating diseases (a group of central nervous system disorders), a follow-up of ...

How have HPV vaccines affected cervical cancer screening?

June 7, 2017
A new review looks at cervical cancer screening in the era of HPV vaccination. The review notes that trials have demonstrated the efficacy and safety of vaccines against HPV infection, but the complete effect of HPV vaccination ...

70-gene signature not cost-effective in breast cancer

October 18, 2014
(HealthDay)—For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published online Oct. 6 in ...

Herpes zoster vaccine not cost-effective in adults aged 50 years

September 8, 2015
(HealthDay)—For adults aged 50 years, herpes zoster (HZ) vaccine does not appear to be cost-effective, according to a study published online Sept. 8 in the Annals of Internal Medicine.

Recommended for you

Big Data shows how cancer interacts with its surroundings

October 23, 2017
By combining data from sources that at first seemed to be incompatible, UC San Francisco researchers have identified a molecular signature in tissue adjacent to tumors in eight of the most common cancers that suggests they ...

Novel therapies for multidrug-resistant bacteria

October 23, 2017
During this innovative study published in PLOS One, researchers found that novel classes of compounds, such as metal-complexes, can be used as alternatives to or to supplement traditional antibiotics, which have become ineffective ...

Key discoveries offer significant hope of reversing antibiotic resistance

October 23, 2017
Resistance to antibiotics is becoming increasingly prevalent and threatens to undermine healthcare systems across the globe. Antibiotics including penicillins, cephalosporins and carbapenems are known as β-lactams and are ...

Symptom burden may increase hospital length of stay, readmission risk in advanced cancer

October 23, 2017
Hospitalized patients with advanced cancer who report more intense and numerous physical and psychological symptoms appear to be at risk for longer hospital stays and unplanned hospital readmissions. The report from a Massachusetts ...

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.